INTEGRATED NETWORK PHARMACOLOGY AND MOLECULAR DOCKING BASED IDENTIFICATION OF ANTI RHEUMATOID ARTHRITIS POTENTIAL OF LANTANA CAMARA
Universal Journal of Pharmaceutical Research · 15.05.2026
DOI: 10.22270/ujpr.v11i2.1544 ↗Kurz gefasst
Fachartikel in der Zeitschrift Universal Journal of Pharmaceutical Research, online erschienen am 15.05.2026. Verfasst von Intan Permata Putri und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aim and Objectives: This study aimed to elucidate the potential anti-rheumatoid arthritis mechanisms of Lantana camara L. using an integrated approach combi-ning LC–HRMS, network pharmacology, and molecular docking.
Methods
From the methanolic extract of L. camara, 83 compounds were identified. Among these, 17 met the drug likeness criteria and were selected for further investigation. Target prediction and disease gene integration revealed 15 overlapping targets associated with RA. Protein-protein interaction (PPI) network analysis and functional enrichment analysis were performed to identify hub targets and key pathways. Molecular docking was then conducted to evaluate binding affinities of selected compounds.
Results
PPI network analysis identified key hub targets such as IL6, APP, MMP2, ITGB2, PLAU, MMP14, TTR, and MPO. Functional enrichment analysis showed significant involvement in the IL-17 signalling pathway. Molecular docking revealed that Compound 19 had the strongest binding affinity to MMP2 (−9.069 kcal/mol), outperforming aspirin, and exhibited binding energy comparable to prednisolone against IL-6 with a greater number of hydrogen bond interactions. Compound 12 also showed notable interactions, albeit with lower affinity.
Conclusion
Compound 19 emerged as a promising multi-target candidate with potential anti-RA activity through modulation of key inflammatory mediators, including IL-6, MMP2, and MPO. These findings support the traditional use of L. camara in rheumatism and highlight its potential as a source of novel anti-inflammatory agents. Further experimental validation is needed. The docking protocol was validated by redocking the native ligand (RMSD < 2.0 Å). Although these in silico findings are promising, experimental validation using in vitro enzyme inhibition assays and in vivo RA animal models is required to confirm the therapeutic potential of Compound 19. Peer Review History: Received 18 February 2026; Reviewed 6 March 2026; Accepted 9 April; Available online 15 May 2026 Academic Editor: Dr. Ahmad Najib, Universitas Muslim Indonesia, Indonesia, ahmad.najib@umi.ac.id Reviewers: Prof. Hassan A.H. Al-Shamahy, Sana'a University, Yemen, shmahe@yemen.net.ye Sarfaraz Ahmed, Global Institute of Pharmaceutical Education and Research, Kashipur, Uttarakhand, India, sarfarazahmed1@gmail.com
Zitieren
APA
Putri, I. P., Agustina, Reka, Ondjo, S. R., Ruslin, & Arba, M. (2026). INTEGRATED NETWORK PHARMACOLOGY AND MOLECULAR DOCKING BASED IDENTIFICATION OF ANTI RHEUMATOID ARTHRITIS POTENTIAL OF LANTANA CAMARA. Universal Journal of Pharmaceutical Research. https://doi.org/10.22270/ujpr.v11i2.1544
Vancouver
Putri IP, Agustina, Reka, Ondjo SR, Ruslin, Arba M. INTEGRATED NETWORK PHARMACOLOGY AND MOLECULAR DOCKING BASED IDENTIFICATION OF ANTI RHEUMATOID ARTHRITIS POTENTIAL OF LANTANA CAMARA. Universal Journal of Pharmaceutical Research. 2026. doi:10.22270/ujpr.v11i2.1544
BibTeX
@article{Putri2026,
author = {Putri, Intan Permata and Agustina and Reka and Ondjo, Siti Rahmawati and Ruslin and Arba, Muhammad},
title = {INTEGRATED NETWORK PHARMACOLOGY AND MOLECULAR DOCKING BASED IDENTIFICATION OF ANTI RHEUMATOID ARTHRITIS POTENTIAL OF LANTANA CAMARA},
journal = {Universal Journal of Pharmaceutical Research},
year = {2026},
doi = {10.22270/ujpr.v11i2.1544}
}
EUVIMED